Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Murali Kesavan"'
Autor:
Alexander P. Bye, Neline Kriek, Tanya Sage, Suzannah J. Rawlings, Catherine Prodger, Murali Kesavan, Charlotte Lees, Stephen Booth, Louise G. Cowen, Kirsty Shefferd, Michael J. Desborough, Jonathan M. Gibbins, Toby A. Eyre
Publikováno v:
Haematologica, Vol 108, Iss 5 (2022)
Externí odkaz:
https://doaj.org/article/91084de43c7345ffaefe97d67355137d
Autor:
Stephen W. Booth, Toby A. Eyre, John Whittaker, Leticia Campo, Lai Mun Wang, Elizabeth Soilleux, Daniel Royston, Gabrielle Rees, Murali Kesavan, Catherine Hildyard, Farasat Kazmi, Nick La Thangue, David Kerr, Mark R. Middleton, Graham P. Collins
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CXD101 in patients with relapsed / refrac
Externí odkaz:
https://doaj.org/article/ed0569a0654b401a969430ba23e234a6
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Despite the development of highly effective, targeted inhibitors of B-cell proliferation and anti-apoptotic pathways in chronic lymphocytic leukemia (CLL), these treatments are not curative, and many patients will develop either intolerance or resist
Externí odkaz:
https://doaj.org/article/47e97ce06a57446692578236e35d70a1
Autor:
Murali Kesavan, Graham P. Collins
Publikováno v:
European Medical Journal Oncology, Vol 6, Iss 1, Pp 79-90 (2018)
This review presents the recent advances in our understanding of the cellular pathogenesis of T cell non-Hodgkin lymphoma (NHL) and the potential of clinically targeted therapies. Patients with T cell NHL continue to face a limited prognosis, with th
Externí odkaz:
https://doaj.org/article/2c8b80f073694d719e672d4a319e7320
Autor:
Murali Kesavan, Danielle Meyrick, Marat Gallyamov, J. Harvey Turner, Sharon Yeo, Giuseppe Cardaci, Nat P. Lenzo
Publikováno v:
Diagnostics, Vol 11, Iss 3, p 515 (2021)
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a significant contributor to the global cancer burden. lutetium-177-prostate-specific membrane antigen radioligand therapy (177Lu-PSMA RLT) is an effective salvage treatment.
Externí odkaz:
https://doaj.org/article/0ba78a99ed934bc7923b5dcbd518f731
Autor:
Sam M. Murray, Maria Barbanti, Cori Campbell, Anthony Brown, Lucia Chen, Jay Dhanapal, Bing Tseu, Omer Pervaiz, Louis Peters, Sally Springett, Robert Danby, Sandra Adele, Eloise Phillips, Tom Malone, Ali Amini, Lizzie Stafford, Alexandra S. Deeks, Susanna Dunachie, Paul Klenerman, Andrew Peniket, Eleanor Barnes, Murali Kesavan
Publikováno v:
British Journal of Haematology. 198:668-679
Allogeneic haematopoietic stem cell transplant (HSCT) recipients remain at high risk of adverse outcomes from coronavirus disease 2019 (COVID-19) and emerging variants. The optimal prophylactic vaccine strategy for this cohort is not defined. T cell-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f12ee93f1e94500856d2da8e0de2596
https://doi.org/10.1111/bjh.18312
https://doi.org/10.1111/bjh.18312
Autor:
Ghassan Zammar, Andrew D McQuillan, James T McQuillan, William Macdonald, Murali Kesavan, J. Harvey Turner
Publikováno v:
British Journal of Haematology. 196:237-241
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79201b078d14d8f217d09476ddc1f892
https://doi.org/10.1111/bjh.17758
https://doi.org/10.1111/bjh.17758
Publikováno v:
Endocrine-Related Cancer. 28:521-527
Thirty-seven patients with advanced gastroenteropancreatic neuroendocrine tumors (GEPNETs) were treated on a prospective phase II single-center study with four cycles of 7.8 GBq 177Lu-octreotate combined with capecitabine and temozolomide chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7b571a54ac9516ff36837b9697d3144
https://doi.org/10.1530/erc-21-0082
https://doi.org/10.1530/erc-21-0082
Autor:
Murali Kesavan, J. Harvey Turner
Publikováno v:
Cancer biotherapyradiopharmaceuticals. 37(3)
Emergent genomic analytic techniques in patients with cancer offer the potential to define the risk of myelo dysplastic syndrome (MDS) and acute leukemia (AL) manifesting following targeted radionuclide therapy of metastatic lymphoma, neuroendocrine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5573db8093d04d41344a50d57b18d3ff
https://pubmed.ncbi.nlm.nih.gov/34871036
https://pubmed.ncbi.nlm.nih.gov/34871036
Autor:
Farasat Kazmi, Leticia Campo, Mark R. Middleton, Toby A. Eyre, Nicholas B. La Thangue, Gabrielle G. Rees, Graham P. Collins, Stephen Booth, Murali Kesavan, Daniel Royston, David J. Kerr, John Whittaker, Lai Mun Wang, Catherine Hildyard, Elizabeth J. Soilleux
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Funder: Oxford Experimental Cancer Centre
Background: This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CX
Background: This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b692505f6b19346560b40340f6f62b7
https://doi.org/10.1186/s12885-021-08595-w
https://doi.org/10.1186/s12885-021-08595-w